Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hereditary Sensory and Autonomic Neuropathies × ribociclib × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 22 Neoplasms by Site 2 Neoplasms 2 Neoplasm Metastasis 2 Multiple Endocrine Neoplasia Type 1 2 Breast Diseases 2 Unilateral Breast Neoplasms 1 Recurrence 1 Osteitis Deformans 1 Hereditary Sensory and Autonomic Neuropathies 1 Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1 Breast Neoplasms, Male 1 Advanced Metastatic Breast Cancer 1

Interventions

Fulvestrant 2 ribociclib 1 duvelisib 1 Secretin 1 Rituximab 1 NVP-BKM120 1 Letrozole 1 CA-19-9 Antigen 1 Aspirin 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03439046 2024-08-01

BioItaLEE

Novartis

Phase 3 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡